Condition

Solid Tumors clinical trials and research

• 96Clinical trials
• 79NIH research projects
• 1New in 30 days
• 51Countries

Newest Solid Tumors clinical trials

All recruiting trials (96)

• BA1203 in advanced solid tumors: safety and early signs of activity

  This early-phase trial tests BA1203 in adults with advanced solid tumors to see if it is safe, tolerable, how the drug behaves in the body, and whether it shows any early signs of effectiveness.

  Recruiting Phase 1 Shandong Boan Biotechnology Co., Ltd · Beijing · NCT07876609

• BL-M08D treatment in melanoma and other solid tumors

  A phase Ib/II study tests BL-M08D1 injections in adults with locally advanced or metastatic melanoma and other solid tumors to see if it is safe and helpful.

  Recruiting Phase 1/2 Sichuan Baili Pharmaceutical Co., Ltd. · Beijing, Beijing Municipality · NCT07841925

• REC-7735 for PIK3CA-H1047R-mutant solid tumors

  This study tests REC-7735 in people with unresectable, locally advanced, or metastatic solid tumors that carry the PIK3CA-H1047R mutation.

  Recruiting at 3 sites Phase 1/2 Recursion Pharmaceuticals Inc. · Grand Rapids, Michigan and 2 other locations · NCT07819136

• Preferences of physicians and patients for cell therapies in advanced solid tumors

  This study tests how doctors and patients weigh the benefits, risks, and burdens of CAR-T, TIL, TCR-T, and NK cell therapies in advanced solid cancers.

  Recruiting Zhejiang University · Hangzhou, Zhejiang · NCT07813000

• HP007 monotherapy for relapsed or advanced solid tumors

  This study tests HP007 as a standalone treatment in adults with hard-to-treat solid tumors to see if it is safe and tolerable and to look for early signs of activity.

  Recruiting Phase 1 Parr Biotechnology (Hebei) Co., Ltd. · Changchun, Jilin · NCT07800936

• ONO-7429 in advanced or recurrent solid tumors

  This small early-phase study tests whether ONO-7429 is tolerable and safe in adults with unresectable advanced or recurrent solid tumors who have tried other treatments.

  Recruiting at 10 sites Phase 1 Ono Pharmaceutical Co., Ltd. · Kashiwa, Chiba and 9 other locations · NCT07787208

• BL-M08D in patients with digestive tract and other solid tumors

  A early-stage study to see if BL-M08D1 can be safely given and help people with advanced digestive tract cancers and other solid tumors.

  Recruiting Phase 1/2 Sichuan Baili Pharmaceutical Co., Ltd. · Beijing, Beijing Municipality · NCT07780318

• BL-ARC002 in patients with advanced solid tumors

  This study tests BL-ARC002 to see if it is safe and tolerable in adults with locally advanced or metastatic solid tumors.

  Recruiting Phase 1 Sichuan Baili Pharmaceutical Co., Ltd. · Guangzhou, Guangdong · NCT07763652

• SI-B036 in head and neck and other solid tumors: a first-in-human study

  This early-phase study tests SI-B036 in adults with locally advanced or metastatic head and neck cancers and other solid tumors to see if it is safe and tolerable, and to get initial clues about its activity.

  Recruiting at 2 sites Phase 1 Sichuan Baili Pharmaceutical Co., Ltd. · Changsha, Hunan and 1 other locations · NCT07763639

• Optimizing Additional Therapies With Immune Checkpoint Inhibitors for Solid Tumors

  This study tests whether avoiding daily acetaminophen and cannabis products while taking aspirin and loratadine can boost the effectiveness of immune checkpoint therapy for people with solid tumors.

  Recruiting Phase 2 University of Kentucky · Lexington, Kentucky · NCT07661459

• IL-15–Enhanced NK Cell Therapy for Solid Tumors

  A first-in-human, early-phase study tests whether IL-15–enhanced engineered NK cells are safe and can show early signs of effect in adults with relapsed or metastatic solid tumors.

  Recruiting Early Phase 1 Genovn Therapeutics PTE. LTD. · Chongqing · NCT07621471

• BL-ARC002 in patients with solid tumors

  This early-phase study tests BL-ARC002 in adults with locally advanced or metastatic solid tumors to see if it is safe and how it behaves in the body, and to look for any signs of benefit.

  Recruiting Phase 1 Sichuan Baili Pharmaceutical Co., Ltd. · Tianjin, Tianjin Municipality · NCT07591155

• KIVU-305 for advanced solid tumors

  This first-in-human study tests KIVU-305, a CEACAM5-targeted antibody-drug conjugate, in adults with locally advanced or metastatic solid tumors that have no good standard options left or are resistant to current therapies.

  Recruiting at 3 sites Phase 1 Kivu Bioscience Inc. · Sydney, New South Wales and 2 other locations · NCT07545356

• Cold exposure with PD-1/PD-L1 immunotherapy in solid tumors

  This phase 1 study tests whether adding controlled cold exposure to standard PD-1/PD-L1 therapy is safe and feasible in adults with solid tumors.

  Recruiting Phase 1 West China Hospital · Chengdu, Sichuan · NCT07538479

• RC288 cancer treatment study for solid tumors

  This trial tests RC288 to see if it is safe and tolerable and whether it works at a recommended dose in adults with solid tumors.

  Recruiting at 4 sites Phase 1/2 RemeGen Co., Ltd. · Hunan, Changsha and 13 other locations · NCT07537881

• 89Zr-s-C1 PET/CT imaging to find MUC18-expressing solid tumors

  This project will test whether a new PET/CT tracer, 89Zr-s-C1, can detect tumor lesions in people with solid tumors and reflect MUC18 expression.

  Recruiting Peking University Cancer Hospital & Institute · Beijing, Beijing Municipality · NCT07529002

• Chemotherapy with or without INCB161734 for untreated KRAS G12D metastatic pancreatic cancer

  This will test whether adding the KRAS G12D blocker INCB161734 to standard chemotherapy helps people with newly diagnosed metastatic pancreatic cancer that has a KRAS G12D mutation.

  Recruiting at 131 sites Phase 3 Incyte Corporation · Birmingham, Alabama and 229 other locations · NCT07522073

• Imaging tissue-factor–positive solid tumors with RT01-89Zr PET/CT

  This study will try a new PET/CT imaging agent called RT01-89Zr in adults with solid tumors that show tissue factor on tumor tests.

  Recruiting Early Phase 1 Nanolattix Biotechnology Co., Ltd. · Wuxi, Jiangsu · NCT07505069

• Navlimetostat for MTAP-deleted solid tumors: monotherapy and combination therapy

  This study tests Navlimetostat alone and with other cancer drugs in people with advanced solid tumors that lack MTAP, to see if it is safe and if it can help shrink tumors.

  Recruiting at 35 sites Phase 2 Bristol-Myers Squibb · San Francisco, California and 57 other locations · NCT07492680

• Lenvatinib plus PD-1 inhibitor for tumors with 11q13 amplification

  This trial tests whether combining lenvatinib with a PD-1 inhibitor can help adults with advanced solid tumors that have 11q13 gene amplification.

  Recruiting Phase 2 Tongji Hospital · Wuhan, Hubei and 1 other locations · NCT07417501

• GEN1106 for solid tumors, including metastatic urothelial (bladder) cancer.

  This trial tests a new drug called GEN1106 in people with metastatic solid tumors, especially urothelial (bladder) cancer, who have progressed after standard treatments.

  Recruiting at 9 sites Phase 1 Genmab · New Haven, Connecticut and 9 other locations · NCT07416123

• Long-term treatment continuation for patients who previously took adagrasib

  This is a continuation study to see if continuing treatment with adagrasib (or in combination with other drugs) helps solid tumor patients who have already benefited from previous adagrasib studies.

  Recruiting at 79 sites Phase 2 Mirati Therapeutics Inc. · Phoenix, Arizona and 100 other locations · NCT07415031

• Testing ZL-6201 for safety and early activity in sarcoma and other solid tumors

  This trial will see if the antibody-drug conjugate ZL-6201 is safe and shows early anti-cancer activity in adults with sarcoma or certain other advanced solid tumors.

  Recruiting at 8 sites Phase 1 Zai Lab (Hong Kong), Ltd. · Los Angeles, California and 7 other locations · NCT07374848

• GK01 with or without chemotherapy after surgical removal of solid tumors

  This trial tries GK01, alone or with chemotherapy, after surgery to help people with resectable solid tumors stay cancer-free.

  Recruiting Phase 1 Tianjin Medical University Cancer Institute and Hospital · Tianjin · NCT07351903

• DPTX3186 for Wnt-pathway activated solid tumors

  This first-in-human study will try an oral drug called DPTX3186 in adults whose solid tumors are driven by the Wnt pathway and who have no approved treatment options left.

  Recruiting at 8 sites Phase 1 Dewpoint Therapeutics · Los Angeles, California and 7 other locations · NCT07312903

• BL-M24D1 treatment for advanced gastrointestinal and other solid tumors

  This trial will test BL-M24D1 in adults with locally advanced or metastatic gastrointestinal and other solid tumors to see if it is safe, tolerated, and shows early signs of anti-tumor activity.

  Recruiting Phase 1 Sichuan Baili Pharmaceutical Co., Ltd. · Beijing, Beijing Municipality · NCT07279428

• Lutetium [177Lu]-BL-ARC001 for advanced lung, breast, head and neck and other solid tumors

  This study will test a radiolabeled drug called Lutetium [177Lu]-BL-ARC001 in adults with advanced or metastatic solid tumors (such as lung, breast, or head and neck cancers) whose standard treatments have not worked.

  Recruiting Phase 1 Sichuan Baili Pharmaceutical Co., Ltd. · Chengdu, Sichuan · NCT07274852

• Phase 1 HDM2017 for advanced solid tumors

  This trial will test an experimental drug called HDM2017 in adults with advanced solid tumors to see if it is safe and has any anti-tumor activity.

  Recruiting Phase 1 Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. · Beijing, Beijing Municipality · NCT07274085

• First-in-human use of 7MW4911 in patients with advanced solid tumors

  This trial will test whether the experimental drug 7MW4911 is safe and shows anti-tumor activity in Chinese adults with advanced solid tumors who have progressed after prior treatments.

  Recruiting Phase 1/2 Mabwell (Shanghai) Bioscience Co., Ltd. · Shanghai, Shanghai Municipality · NCT07265622

• Interferon patterns in cancer patients receiving CTLA-4 or PD-1/PD-L1 inhibitors versus autoimmune disease

  This project will test whether blood interferon levels can help predict immune-related side effects in adults starting checkpoint inhibitor immunotherapy by comparing them with people who have autoimmune diseases.

  Recruiting Hospital Universitario Araba · Pamplona, Navarre · NCT07249060

• Lutetium‑177 BL‑ARC001 for advanced or metastatic gastrointestinal and other solid tumors

  This trial will test whether Lutetium‑177 BL‑ARC001 is safe and shows early benefit in adults with locally advanced or metastatic gastrointestinal or other solid tumors.

  Recruiting Phase 1 Sichuan Baili Pharmaceutical Co., Ltd. · Chengdu, Sichuan · NCT07232407

• SHR-4610 injection for advanced solid tumors

  This trial will test SHR-4610 injection to see if it helps adults (18–75) with unresectable or metastatic solid tumors that have not responded to standard treatments.

  Recruiting Phase 1/2 Shanghai Shengdi Pharmaceutical Co., Ltd · Hangzhou, Zhejiang · NCT07231211

• INCA036873 for adults with advanced solid tumors and blood cancers.

  This trial will test whether the experimental drug INCA036873 is safe and tolerable in adults with advanced or metastatic solid tumors or certain blood cancers who have already tried standard treatments.

  Recruiting at 19 sites Phase 1 Incyte Corporation · Duarte, California and 21 other locations · NCT07195916

• BG-C0902 alone and with other therapies for people with advanced solid tumors

  This study will test whether BG-C0902, given alone or with other cancer drugs, is safe and can shrink tumors in people with advanced solid tumors.

  Recruiting at 15 sites Phase 1 BeOne Medicines · Houston, Texas and 14 other locations · NCT07181681

• DS3610a for adults with advanced or metastatic solid tumors

  This trial will test whether DS3610a is safe and helps adults with advanced or metastatic solid tumors.

  Recruiting at 4 sites Phase 1 Daiichi Sankyo · Milwaukee, Wisconsin and 3 other locations · NCT07159126

• ABL103 plus pembrolizumab, with or without taxane, for advanced or metastatic solid tumors

  This trial will try ABL103 together with pembrolizumab, with or without a taxane chemotherapy, in adults with advanced or metastatic solid tumors who have relapsed on or cannot tolerate standard treatments.

  Recruiting at 2 sites Phase 1/2 ABL Bio, Inc. · Cleveland, Ohio and 5 other locations · NCT07158918

• XB371 for people with locally advanced or metastatic solid tumors

  This trial will test whether XB371 is safe and tolerable in people with locally advanced or metastatic solid tumors.

  Recruiting at 9 sites Phase 1 Exelixis · Rogers, Arkansas and 8 other locations · NCT07123103

• RC278 treatment for people with solid tumors.

  This trial will test whether RC278 is safe and can shrink measurable solid tumors in adults.

  Recruiting at 39 sites Phase 1/2 RemeGen Co., Ltd. · Beijing, Beijing Municipality and 38 other locations · NCT07105215

• SOA101 safety and early effectiveness in adults with advanced solid tumors.

  This will test SOA101, a nanobody-based trispecific antibody that engages T cells, to see if it's safe and helps adults with advanced or metastatic solid tumors that express PD-L1.

  Recruiting Phase 1/2 Shine-On Biomedical Co., Ltd. · Taichung · NCT07055594

• Romiplostim N01 for chemotherapy-related low platelets in children and young adults

  Romiplostim N01 will be tried to raise platelet counts in children and young adults (ages 6–24) who develop low platelets after chemotherapy for solid tumors or blood cancers.

  Recruiting Phase 2 Cancer Institute and Hospital, Chinese Academy of Medical Sciences · Beijing · NCT07043894

• DCSZ11 combined with standard therapy for advanced or metastatic solid tumors

  This will test whether adding DCSZ11 to standard treatments helps adults with advanced or metastatic solid tumors.

  Recruiting Phase 1/2 West China Hospital · Chengdu, Sichuan · NCT07035249

• HRS-7058 with other anti-cancer drugs for adults with solid tumors

  This trial will test whether adding HRS-7058 to other anti-cancer drugs is safe and helps shrink tumors in adults with solid tumors.

  Recruiting Phase 2 Shandong Suncadia Medicine Co., Ltd. · Beijing, Beijing Municipality · NCT07032077

• AUBE00 for advanced or metastatic solid tumors with KRAS alterations

  This trial will test AUBE00, alone and with cetuximab, in adults with advanced or metastatic KRAS‑altered solid tumors who have exhausted standard therapies.

  Recruiting at 5 sites Phase 1 Chugai Pharmaceutical · Grand Rapids, Michigan and 4 other locations · NCT07030959

• Protecting your kidneys during cisplatin or carboplatin chemotherapy

  This tests whether the diabetes medicine dapagliflozin can protect the kidneys of adults with solid tumors who are receiving cisplatin or carboplatin chemotherapy.

  Recruiting Phase 2 Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran · México, Tlalpan · NCT07018622

• CBA-1535 (5T4/CD3) T‑cell engager given alone and with pembrolizumab for advanced solid tumors

  This trial tests whether CBA-1535, a T‑cell engager that targets 5T4, is safe and shows early signs of benefit when given alone or with pembrolizumab to people with advanced solid tumors who have no standard treatment options.

  Recruiting at 2 sites Phase 1 Chiome Bioscience Inc. · Nagaizumicho, Shizuoka and 1 other locations · NCT07016997

• Personalized neoantigen peptide vaccine for solid tumors

  This trial will test whether a custom neoantigen peptide vaccine given with poly-ICLC and an anti-PD-1 drug can help the immune system fight solid tumors in adults with advanced or high-risk disease.

  Recruiting Phase 1/2 Seqker Biosciences, Inc. · Bangkok · NCT07002203

• PEP08 for adults with advanced MTAP‑deleted solid tumors

  This trial will test whether PEP08, given alone or with another cancer drug, is safe and shows signs of benefit in adults with advanced or metastatic solid tumors that have MTAP deletion.

  Recruiting at 4 sites Phase 1 PharmaEngine · Wentworthville, New South Wales and 3 other locations · NCT06973863

• Treatment with IBI3020 for patients with late-stage solid tumors

  This study is testing a new treatment called IBI3020 to see if it is safe and what the best dose is for people with late-stage solid tumors who haven't had success with other therapies.

  Recruiting at 9 sites Phase 1 Fortvita Biologics (USA)Inc. · Phoenix, Arizona and 8 other locations · NCT06963281

• Evaluating SYS6005 for advanced malignant tumors

  This study is testing a new treatment called SYS6005 to see if it is safe and effective for people with advanced malignant tumors.

  Recruiting Phase 1 CSPC Megalith Biopharmaceutical Co.,Ltd. · Tianjin · NCT06958679

• DB-1311 plus BNT327 or DB-1305 for advanced solid tumors

  This trial tests whether combining the experimental drug DB-1311 with BNT327 or with DB-1305 can help adults with advanced or metastatic solid tumors such as HCC, cervical cancer, melanoma, head and neck cancer, platinum-resistant ovarian cancer, or non-small cell lung cancer.

  Recruiting at 37 sites Phase 2 DualityBio Inc. · Los Angeles, California and 36 other locations · NCT06953089

• Telpegfilgrastim versus filgrastim to prevent low white blood counts after chemotherapy in children and young adults

  This study tries to see if a single long‑acting injection of telpegfilgrastim can reduce febrile neutropenia compared with daily filgrastim in 6–24‑year‑olds receiving high‑intensity chemotherapy for solid tumors.

  Recruiting Phase 2 Cancer Institute and Hospital, Chinese Academy of Medical Sciences · Beijing · NCT06926751

• Evaluating TYRA-430 for advanced liver and solid tumors with specific genetic changes

  This study is testing a new drug called TYRA-430 to see if it can help people with advanced liver and other solid tumors that have certain genetic changes.

  Recruiting at 15 sites Phase 1 Tyra Biosciences, Inc · Los Angeles, California and 15 other locations · NCT06915753

• HS-20110 for adults with advanced solid tumors

  HS-20110 will be tested for safety and tolerability in adults with advanced solid tumors who have at least one measurable tumor outside the brain.

  Recruiting at 8 sites Phase 1 Hansoh BioMedical R&D Company · Tamarac, Florida and 7 other locations · NCT06892379

• ZL-1310 for selected advanced solid tumors

  This will try the drug ZL-1310 in adults with selected advanced or metastatic solid tumors, especially neuroendocrine carcinomas that have progressed after platinum-based chemotherapy.

  Recruiting at 23 sites Phase 1/2 Zai Lab (Hong Kong), Ltd. · San Francisco, California and 22 other locations · NCT06885281

• Evaluating DC05F01 for patients with recurrent ovarian cancer and advanced solid tumors

  This study is testing a new oral treatment called DC05F01 to see if it can help people with recurrent ovarian cancer and other advanced solid tumors feel better.

  Recruiting at 2 sites Phase 1/2 Heronova Pharmaceuticals · Bengbu, Anhui and 1 other locations · NCT06873555

• Intravenous VRT106 for locally advanced or metastatic solid tumors

  This Phase 1 trial will test whether an intravenous medicine called VRT106 is safe and tolerable for adults (18–75) with locally advanced or metastatic solid tumors who have run out of standard treatment options.

  Recruiting Phase 1 Guangzhou Virotech Pharmaceutical Co., Ltd. · Guangzhou, Guangdong · NCT06826313

• Combining ORIC-114 with Amivantamab for NSCLC with EGFR Exon 20 Insertion Mutations

  This study is testing a new combination of two drugs, ORIC-114 and amivantamab, to see if they can help people with advanced lung cancer that has a specific genetic mutation.

  Recruiting at 2 sites Phase 1 ORIC Pharmaceuticals · New York, New York and 3 other locations · NCT06816992

• PumaRx Registry for RenovoCath delivery to solid tumors

  This registry follows adults with solid tumors to track how the RenovoCath catheter performs and how patients do after cancer medicines are delivered directly into tumors through arteries.

  Recruiting at 3 sites RenovoRx · Coral Gables, Florida and 2 other locations · NCT06805461

• Testing a new drug for patients with advanced solid tumors

  This study is testing a new drug called JR8603 to see if it can help people with advanced solid tumors that haven't responded to other treatments.

  Recruiting at 2 sites Phase 1 JiaRay Group · Harbin, Heiljiang Province and 1 other locations · NCT06783569

• Evaluating SHR-4375 for patients with solid tumors

  This study is testing a new treatment called SHR-4375 to see if it can help people with advanced solid tumors who haven't had success with other therapies.

  Recruiting Phase 1/2 Suzhou Suncadia Biopharmaceuticals Co., Ltd. · Shanghai, Shanghai Municipality · NCT06764628

• Liposomal mitoxantrone combined with capecitabine and anlotinib for relapsed and refractory solid tumors in children, adolescents, and young adults

  This treatment tests whether a liposomal mitoxantrone combination (with capecitabine and anlotinib) can shrink relapsed or refractory solid tumors in children, adolescents, and young adults.

  Recruiting Phase 2 Cancer Institute and Hospital, Chinese Academy of Medical Sciences · Beijing · NCT06761417

• Injecting a viral particle to treat head and neck cancer

  This study is testing a new virus injection to see if it can help treat head and neck cancer in different groups of patients.

  Recruiting Phase 1 VLP Therapeutics · Stanford, California · NCT06736379

• Testing HRS-6208 for patients with advanced solid tumors

  This study is testing a new treatment called HRS-6208 to see if it is safe and helps people with advanced solid tumors that can't be treated with standard options.

  Recruiting at 2 sites Phase 1 Shandong Suncadia Medicine Co., Ltd. · Nanjing, Jiangsu and 1 other locations · NCT06727812

• Testing ADRX-0405 in patients with advanced solid tumors

  This study is testing a new treatment called ADRX-0405 to see if it is safe and effective for people with advanced solid tumors like prostate, gastric, and lung cancer.

  Recruiting at 8 sites Phase 1 Adcentrx Therapeutics · Duarte, California and 7 other locations · NCT06710379

• SAR444881 plus cemiplimab for advanced solid tumors

  This trial tests SAR444881 together with cemiplimab in adults with advanced solid tumors (including non‑small cell lung, MSS colorectal, and ovarian cancer) to look for biomarkers tied to response and safety.

  Recruiting Phase 2 M.D. Anderson Cancer Center · Houston, Texas · NCT06651593

• Testing DS-2243a for advanced solid tumors

  This study is testing a new treatment called DS-2243a to see if it helps people with advanced solid tumors like certain types of sarcoma, lung cancer, and bladder cancer.

  Recruiting at 7 sites Phase 1 Daiichi Sankyo · Boston, Massachusetts and 6 other locations · NCT06644755

• Testing a new antibody treatment for advanced solid tumors and liver cancer

  This study is testing a new antibody treatment for people with advanced solid tumors and liver cancer to see if it is safe and how well it works.

  Recruiting at 5 sites Phase 1 Chiome Bioscience Inc. · Kashiwa, Chiba and 4 other locations · NCT06636435

• Evaluating ABSK061 and ABSK043 for treating advanced solid tumors

  This study is testing a new combination of two drugs to see if they can help people with advanced solid tumors that have specific genetic changes.

  Recruiting Phase 2 Abbisko Therapeutics Co, Ltd · Guiyang, Guizhou and 20 other locations · NCT06632262

• Testing HS-20117 with other drugs for advanced solid tumors

  This study is testing a new drug called HS-20117, along with other treatments, to see if it can help people with advanced solid tumors like non-small cell lung cancer and colorectal cancer.

  Recruiting Phase 1 Hansoh BioMedical R&D Company · Tianjin · NCT06621563

• Testing HSK42360 for solid tumors with BRAF V600 mutation

  This study is testing a new oral medication called HSK42360 to see if it is safe and helpful for people with advanced solid tumors that have a specific BRAF V600 mutation.

  Recruiting at 13 sites Phase 1 Haisco Pharmaceutical Group Co., Ltd. · Beijing, Beijing Municipality and 12 other locations · NCT06536400

• Evaluating GSK5733584 for advanced solid tumors

  This study is testing a new injectable treatment called GSK5733584 to see if it's safe and how it works for people with advanced solid tumors that haven't responded to other treatments.

  Recruiting at 64 sites Phase 1 GlaxoSmithKline · Birmingham, Alabama and 64 other locations · NCT06431594

• FTL008.16 safety test for adults with advanced solid tumors

  This will test FTL008.16, an experimental drug, in adults with advanced or metastatic solid tumors to see if it is safe and to collect early signs of benefit.

  Recruiting Phase 1 Sound Biopharmaceuticals Ltd. · Beijing, Beijing Municipality · NCT06410131

• Treatment with JAB-30355 for patients with advanced solid tumors and a specific genetic mutation

  This study is testing a new treatment called JAB-30355 to see if it can help adults with advanced solid tumors that have a specific genetic mutation called TP53 Y220C.

  Recruiting at 13 sites Phase 1/2 Jacobio Pharmaceuticals Co., Ltd. · Denver, Colorado and 14 other locations · NCT06386146

• Testing QTX3034 for patients with KRAS G12D mutation in solid tumors

  This study is testing a new treatment called QTX3034, alone and with another drug, to see if it can help patients with solid tumors that have a specific KRAS G12D mutation and haven't responded to other therapies.

  Recruiting at 14 sites Phase 1 Quanta Therapeutics · Los Angeles, California and 13 other locations · NCT06227377

• Evaluating INCB161734 for advanced solid tumors with KRAS G12D mutation

  This study is testing a new drug called INCB161734, alone and with other cancer treatments, to see if it can help people with advanced solid tumors that have a specific KRAS G12D mutation.

  Recruiting at 34 sites Phase 1 Incyte Corporation · Phoenix, Arizona and 33 other locations · NCT06179160

• Testing TROP2 CAR-engineered NK cells in patients with advanced solid tumors

  This study is testing a new treatment using specially engineered immune cells to see if they can help people with advanced solid tumors that have high levels of a protein called TROP2.

  Recruiting Phase 1 M.D. Anderson Cancer Center · Houston, Texas · NCT06066424

• Evaluating the safety of INCA33890 for advanced or metastatic solid tumors

  This study is testing a new drug called INCA33890 to see if it's safe for people with advanced solid tumors who haven't had success with other treatments.

  Recruiting at 36 sites Phase 1 Incyte Corporation · Los Angeles, California and 38 other locations · NCT05836324

• Evaluating a new treatment for advanced solid tumors

  This study is testing a new treatment called BA1106 to see if it is safe and effective for people with advanced solid tumors.

  Recruiting Phase 1 Shandong Boan Biotechnology Co., Ltd · Beijing, Beijing Municipality · NCT05650242

• Evaluating AB521 for kidney cancer and other solid tumors

  This study is testing a new treatment called casdatifan, alone and with other medications, to see if it helps people with advanced kidney cancer and other solid tumors feel better.

  Recruiting at 24 sites Phase 1 Arcus Biosciences, Inc. · Birmingham, Alabama and 24 other locations · NCT05536141

• Assessing the effectiveness and safety of FORE8394 for cancer with BRAF alterations

  This study is testing a new cancer treatment called plixorafenib to see if it helps people with certain BRAF gene changes and advanced tumors feel better and live longer after other treatments have failed.

  Recruiting at 67 sites Phase 2 Fore Biotherapeutics · Beverly Hills, California and 69 other locations · NCT05503797

• Evaluating JAB-2485 for Advanced Solid Tumors

  This study is testing a new drug called JAB-2485 to see if it is safe and can help adults with advanced solid tumors, like certain types of breast cancer and lung cancer, who have already tried other treatments.

  Recruiting at 8 sites Phase 1/2 Jacobio Pharmaceuticals Co., Ltd. · Detroit, Michigan and 7 other locations · NCT05490472

• Testing a new cancer treatment with BI 1703880 and ezabenlimab

  This study is testing a new cancer treatment combining two medications to see if they can help adults with advanced tumors that haven’t responded to other treatments.

  Recruiting at 13 sites Phase 1 Boehringer Ingelheim · Los Angeles, California and 20 other locations · NCT05471856

• Treatment with ORIC-114 for advanced solid tumors with EGFR or HER2 alterations

  This study is testing a new drug called ORIC-114 to see if it can help people with advanced solid tumors that have specific genetic changes related to EGFR or HER2.

  Recruiting at 42 sites Phase 1/2 ORIC Pharmaceuticals · Duarte, California and 41 other locations · NCT05315700

• Continued access to encorafenib and binimetinib for previous trial participants

  This study is for people who have previously taken the medications encorafenib and binimetinib and want to continue using them safely for up to five years if they are still benefiting from the treatment.

  Recruiting at 62 sites Phase 4 Pfizer · Phoenix, Arizona and 76 other locations · NCT05203172

• Testing S-531011 alone and with an immune therapy for advanced solid tumors

  This study is testing a new treatment called S-531011, both alone and with an immune therapy, to see if it can help people with advanced solid tumors that haven't responded to other treatments.

  Recruiting at 6 sites Phase 1/2 Shionogi Inc. · Los Angeles, California and 7 other locations · NCT05101070

• Combining Envafolimab and Lenvatinib for treating advanced solid tumors

  This study is testing if combining two drugs, Envafolimab and Lenvatinib, can help people with advanced solid tumors feel better when other treatments haven't worked.

  Recruiting at 16 sites Phase 1/2 3D Medicines · Bengbu, Anhui and 22 other locations · NCT05024214

• Testing ICP-723 for advanced solid tumors

  This study is testing a new drug called ICP-723 to see how safe it is and how well it works for people with advanced solid tumors that can't be removed by surgery.

  Recruiting at 24 sites Phase 1/2 Beijing InnoCare Pharma Tech Co., Ltd. · Hefei, Anhui and 23 other locations · NCT04685226

• Evaluating eflapegrastim for children with solid tumors or lymphomas undergoing chemotherapy

  This study is testing a new drug called eflapegrastim to see if it can help children with solid tumors or lymphomas feel better while they are getting chemotherapy.

  Recruiting Phase 2 Spectrum Pharmaceuticals, Inc · Valhalla, New York and 4 other locations · NCT04570423

• Using ponatinib to treat children with advanced leukemias, lymphomas, or solid tumors

  This study is testing if ponatinib can help children with hard-to-treat leukemias, lymphomas, or solid tumors feel better and have more treatment options.

  Recruiting at 22 sites Phase 1/2 Incyte Corporation · Ghent and 22 other locations · NCT03934372

• Exploring biomarkers to predict tumor response to radiotherapy

  This study is trying to find markers in tumors and blood that can help predict how well solid tumors will respond to radiotherapy in patients who need this treatment.

  Recruiting Shantou University Medical College · Shantou, Guangdong · NCT03744819

• Long-term evaluation of pembrolizumab for patients with advanced tumors

  This study is testing how well pembrolizumab works and how safe it is for people with advanced tumors who have already been part of previous studies.

  Recruiting at 472 sites Phase 3 Merck Sharp & Dohme LLC · Tucson, Arizona and 781 other locations · NCT03486873

• Testing a new drug for advanced solid tumors

  This study is testing a new drug called Aza-TdC to see if it can help people with advanced solid tumors that haven't improved with standard treatments.

  Recruiting Phase 1 National Institutes of Health Clinical Center (CC) · Bethesda, Maryland · NCT03366116

• Treatment of advanced solid tumors with APL-101 for specific genetic mutations

  This study is testing a new oral medication called APL-101 to see if it helps people with advanced lung cancer and other solid tumors that have certain genetic changes, especially those who haven't had success with standard treatments.

  Recruiting at 32 sites Phase 2 Apollomics Inc. · Los Angeles, California and 34 other locations · NCT03175224

• Mayo Clinic radiotherapy outcomes registry and biobank

  This project collects blood and tissue from people with solid tumors or blood cancers treated with photon or proton radiotherapy at Mayo Clinic Rochester to see if biological markers link to side effects and outcomes.

  Recruiting Mayo Clinic · Rochester, Minnesota · NCT02457962

• Genomic profiling to identify mutations in cancer patients

  This study is trying to find out how changes in genes from tumor and normal tissue samples can affect how cancer patients respond to new treatments.

  Recruiting at 16 sites Memorial Sloan Kettering Cancer Center · Bridgeport, Connecticut and 17 other locations · NCT01775072

• Comprehensive database for studying stem cell transplants and cellular therapies

  This study is creating a database to gather information on stem cell transplants and treatments to help improve recovery for patients and donors and make these therapies more accessible to everyone.

  Recruiting at 2 sites Center for International Blood and Marrow Transplant Research · Minneapolis, Minnesota and 1 other locations · NCT01166009

NIH-funded research (newest 40 of 79)

Early-stage science funded by the US National Institutes of Health. Most of these projects don't enroll patients, but they show what is being worked on.

• Pediatric Preclinical In Vivo Testing Center for Pediatric Sarcoma and Other Solid Tumors

  A program uses mouse tumor models to identify promising drug candidates for children with sarcoma and other solid tumors.

  NIH research Sloan-Kettering Inst Can Research · New York, United States · NIH-11534528

• Engineered CAR T immune cells targeting GPC3 for children's solid tumors

  Engineered CAR T immune cells that produce IL-15 and IL-21 to better find and fight GPC3-positive solid tumors in children.

  NIH research Seattle Children's Hospital · Seattle, United States · NIH-11468394

• Boosting CAR T cell power in solid tumors by turning on transcription factors

  A new research project tests whether turning on specific human transcription factors can make CAR T cells work better against solid tumors.

  NIH research Broad Institute, INC. · Cambridge, United States · NIH-11453755

• Engineering CD19 mimotopes to boost and broaden CD19-CAR T cell therapy

  A patient-focused look at improving existing CD19-CAR T cell therapy so more people with blood cancers might benefit.

  NIH research Children's Hosp of Philadelphia · Philadelphia, United States · NIH-11449957

• Radio-triggered CAR-T cells to better control solid tumors

  A new approach uses radiation to turn on and guide CAR-T cells to fight solid tumors more effectively, potentially improving local and distant tumor control for patients with cancer.

  NIH research University of Chicago · Chicago, United States · NIH-11449605

• Understanding how cell behavior changes drive breast cancer in 3D cultures

  Researchers are studying how breast cells transition toward cancer using advanced 3D cultures and patient-derived samples to uncover important cell-state changes.

  NIH research University of Virginia · Charlottesville, United States · NIH-11444365

• Targeting RNF166 to prevent T-cell exhaustion in solid tumors

  Aims to boost cancer-fighting T cells by modulating RNF166 to keep T cells active and persistent in solid tumors.

  NIH research Univ of Arkansas for Med Scis · Little Rock, United States · NIH-11425205

• Next-generation T cells against KRAS-mutant cancers

  A new type of engineered T cells designed to target KRAS-mutant solid tumors in adults, with early clinical testing planned.

  NIH research University of Pennsylvania · Philadelphia, United States · NIH-11419566

• Expanding access to perioperative and repurposed cancer drug trials

  This grant helps Emory broaden participation in nodal cancer trials and repurposed-drug studies to improve care for people with melanoma and other solid tumors.

  NIH research Emory University · Atlanta, United States · NIH-11416796

• MetaboCore: A quick needle-biopsy test to guide drug choices for solid tumors

  A fast, tissue-based test from a needle biopsy helps doctors pick the best drugs for a patient’s solid tumor.

  NIH research University of Washington · Seattle, United States · NIH-11415590

• CB-101: A new kind of cancer-fighting antibody that redirects T cells to tumors

  A first-in-class antibody therapy called CB-101 is being developed to help treat colorectal cancer and other solid tumors by guiding T cells to attack cancer cells while reducing damage to healthy tissue.

  NIH research Xtop Biotherapeutics INC. · Worcester, United States · NIH-11407471

• Plant virus-based immunotherapy for solid tumors

  A small, early-stage program aims to develop a plant virus-based therapy injected into tumors to help the body fight solid cancers.

  NIH research Plantiosx INC · San Diego, United States · NIH-11402144

• Understanding why CAR T cells struggle in solid tumors

  Scientists are studying why CAR T cell therapy works well for blood cancers but not as well for solid tumors, using advanced tissue analyses from multiple clinical trials.

  NIH research University of Pennsylvania · Philadelphia, United States · NIH-11399836

• Oral Microbiome–Based Aid to Immunotherapy for Refractory Solid Tumors

  A mouth-to-tumor therapy using a probiotic-like approach to help immune checkpoint drugs work better for patients whose solid tumors don’t respond well to current treatments.

  NIH research Rise Therapeutics, LLC · Rockville, UNITED STATES · NIH-11399439

• Broadly targeted peptide-drug conjugate to treat solid tumors

  A new therapy using a peptide that homes in on tumor markers to deliver a potent cancer drug directly to solid tumors in order to reduce harm to healthy tissue.

  NIH research Twostep Therapeutics, INC. · San Carlos, United States · NIH-11390848

• Off-the-shelf iPSC-derived NK cells to fight solid tumors

  A researcher at the University of Minnesota is advancing a patient-focused NK cell therapy using lab-grown, pluripotent stem cell–derived natural killer cells to target solid cancers.

  NIH research University of Minnesota · Minneapolis, United States · NIH-11377095

• Innovative mRNA vaccines to boost T-cell therapy for solid tumors

  A study at UCLA will explore new mRNA vaccines designed to enhance how T cells attack solid tumors like pancreatic cancer.

  NIH research University of California Los Angeles · Los Angeles, United States · NIH-11374934

• Bioinspired virus-like vaccines to boost CAR T and innate T cells against solid tumors

  A patient-focused immune-therapy approach aims to help people with solid tumors by boosting CAR T and natural T cells to attack tumors that vary in the targets they express.

  NIH research Children's Hosp of Philadelphia · Philadelphia, United States · NIH-11367505

• Improving CAR-T therapy for solid tumors by boosting stem-like CAR-T cells in lymph nodes

  A cancer research grant aims to make CAR-T cell therapy work better for solid tumors by increasing a special stem-like group of CAR-T cells in the body's lymph nodes.

  NIH research Fred Hutchinson Cancer Center · Seattle, United States · NIH-11364934

• Fecal microbiota transplantation plus immune checkpoint blockers for solid tumors

  This project looks at whether changing gut bacteria with fecal transplants can boost how well cancer treatments called immune checkpoint blockers work in people with solid tumors.

  NIH research University of Pittsburgh at Pittsburgh · Pittsburgh, United States · NIH-11364138

• VEL-03: a new treatment approach for lung cancer and other solid tumors

  A new drug candidate called VEL-03 aims to slow or stop the growth of non-small cell lung cancer and other solid tumors by targeting cancer cell metabolism.

  NIH research Velorum Therapeutics INC. · Plano, United States · NIH-11345350

• Engineered immune cells that activate only inside breast tumors

  This project develops CAR T cells that switch on only when they detect both tumor proteins and tumor chemicals, aiming to attack breast tumors while sparing healthy tissue.

  NIH research Columbia University Health Sciences · New York, United States · NIH-11314563

• Remote-controlled PC-CAR T cells for hard-to-treat solid tumors

  A new drug-free approach aims to let immune cells recognize and fight certain solid cancers by remotely adjusting their activity against tumor targets.

  NIH research Mabswitch, INC. · Van Nuys, United States · NIH-11313251

• Engineered T cells that precisely target mesothelioma tumors

  The team is building engineered T cells that recognize two tumor signals to better find and kill mesothelioma tumors while sparing healthy tissue.

  NIH research University of California, San Francisco · San Francisco, United States · NIH-11308329

• Virus-loaded immune cells that trigger tumor self-destruction (autosis)

  This project uses tumor-targeting T cells loaded with a harmless virus to make resistant solid tumors self-destruct, offering new hope for people with hard-to-treat solid cancers.

  NIH research Methodist Hospital Research Institute · Houston, United States · NIH-11302625

• Engineered T cells that release TNF-alpha to better attack solid tumors

  This work aims to make engineered T cells that release a helpful immune protein called TNF-alpha at the tumor site to improve treatment for people with solid cancers.

  NIH research University of California Los Angeles · Los Angeles, United States · NIH-11300997

• Image-guided, flexible CAR T therapy for solid tumors

  A new, image-guided CAR T approach uses a universal adaptor to target solid tumors and help predict where therapy goes, aiming to reduce relapse and off-target effects.

  NIH research Methodist Hospital Research Institute · Houston, United States · NIH-11282814

• Combinatorial Pulsed Field Ablation for Solid Tumors

  A new, minimally invasive treatment uses ultrashort electrical pulses to ablate solid tumors near critical organs, aiming to destroy cancer cells while protecting nearby tissues and boosting the body’s immune response.

  NIH research North Carolina State University Raleigh · Raleigh, United States · NIH-11277303

• Improving immune cell entry into solid tumors by targeting AAK1

  This project tests whether blocking a protein called AAK1 can help adoptive immune cell therapies like CAR-T get into solid tumors better for people with cancer.

  NIH research Mayo Clinic Rochester · Rochester, United States · NIH-11264845

• Using virus-trained immune cells to help fight solid tumors

  This project will try reawakening virus-fighting immune cells inside tumors to help people with solid cancers.

  NIH research Dartmouth College · Hanover, United States · NIH-11250987

• A tumor time machine to trace how cancers evolve

  This project builds computer methods that read single-cell DNA from solid tumors to reconstruct their past changes and spot the cell groups most likely to drive future spread.

  NIH research University of Washington · Seattle, United States · NIH-11238577

• Using tumor-targeting viruses to boost CAR T cell treatment for solid tumors

  This work aims to help CAR T cell therapy work better for people with solid tumors by combining CAR T cells with cancer-killing viruses that ramp up the immune response.

  NIH research Mayo Clinic Rochester · Rochester, United States · NIH-11237992

• Teaching CAR T cells to recognize solid tumors using signals from cancer and nearby cells

  This project develops engineered immune cells that look for combinations of markers on tumor and surrounding cells so they can find and kill solid tumors more precisely.

  NIH research University of California, San Francisco · San Francisco, United States · NIH-11232303

• Using virus-specific immune cells to fight solid tumors

  This study is looking at how special immune cells that remember past viral infections can be used to help fight cancer by boosting the body’s ability to attack tumors, and it aims to create a new treatment that could improve outcomes for cancer patients.

  NIH research Dartmouth College · Hanover, United States · NIH-11210729

• Why CAR T-cell therapy helps some solid tumors but not others

  This project uses advanced tissue-level testing to learn why CAR T-cell therapy helps some people with solid cancers like pancreatic and prostate cancer and not others.

  NIH research University of Pennsylvania · Philadelphia, United States · NIH-11195013

• Needle‑biopsy lab test to find which drugs work on solid tumors

  A fast lab test uses a small needle biopsy and a metabolic readout to show which cancer drugs change tumor cells for people with solid tumors.

  NIH research University of Washington · Seattle, United States · NIH-11194977

• Off-the-shelf CAR‑engineered iNKT cell therapy for solid tumors

  Developing an off-the-shelf immune cell treatment using engineered iNKT cells to fight solid tumors in patients.

  NIH research University of Pennsylvania · Philadelphia, United States · NIH-11173894

• Improving CAR T cell therapy for lung and other solid tumors

  This project works to make CAR T cell therapy more effective for people with lung and other solid tumors by building realistic tumor models and testing ways to overcome the tumors' immune defenses.

  NIH research Icahn School of Medicine at Mount Sinai · New York, United States · NIH-11169974

• A new immunotherapy to improve solid tumor treatment

  This project is developing a new type of immunotherapy to help more people with solid tumors like lung cancer and melanoma.

  NIH research Sonoval LLC · Gaithersburg, United States · NIH-11168862

• Using specially designed immune cells to fight solid tumors

  This research aims to create powerful, ready-to-use immune cells from stem cells to target and destroy advanced solid tumors.

  NIH research University of Minnesota · Minneapolis, United States · NIH-11162408

Related topics

Quick answers

How many Solid Tumors clinical trials are recruiting right now?

96, as of November 12, 2026. 1 of them was first registered in the last 30 days. We update this list each time we refresh our data from ClinicalTrials.gov.

Where are these trials running?

In 51 countries. The most sites are in China (53 trials), United States (44 trials), Australia (17 trials), Spain (15 trials), Japan (15 trials). Each study page lists its sites and which ones are recruiting.

What phases are they in?

Phase 1: 47, Phase 1/2: 21, Phase 2: 15, Phase 3: 2. Trials with no phase listed are usually device, behavioural or observational studies.

How do I join one?

Open a study, check the "Is this trial a fit for you?" section, then contact the study team listed on the page. They will ask a few screening questions. Asking is free and does not commit you to anything. Talk it over with your doctor first.

Find the studies that fit you

A list is a starting point. Tell us your situation in your own words and we'll rank the studies that match and explain why. It's free and needs no account.

Describe your situation →